<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Contact Us Select Models
Select Models
Platforms_05

CDX Models

Drive Proof of Concept and Target Validation with Champions’ CDX Models

Application-driven, target-rich, and connected to the most powerful translational platforms in oncology research

Overview

Designed for Early-Stage Confidence

Champions’ CDX platform provides a fast and reproducible entry point into oncology research. Each model is supported by robust validation data, including documented growth kinetics and responses to standards of care, giving researchers confidence in early proof of concept studies. By building trust in the data at the very first stage of development, our CDX models help you prioritize the right compounds before advancing into more complex systems.
16
cell_lines_banner

New

Enabling Smarter Selection with the Cell Model Bank Tool

Choosing the right model should not slow down your research. The Cell Model Bank Tool makes it easy to search Champions’ CDX panel by tumor indication, gene mutation, and gene expression. This first of its kind resource simplifies model selection and reduces the time from inquiry to study start.
Try Now

Rapid Development

Applications That Accelerate Development

CDX models play a central role in early decision making. They are widely used to generate proof of concept data that guides go, no go choices, explore mechanisms of drug resistance, and evaluate potential synergies in combination therapy studies. For developers of antibody drug conjugates (ADCs) and radiopharmaceuticals, Champions offers models that exhibit high target expression. These models provide an efficient way to validate target engagement, assess therapeutic payload delivery, and build confidence in early development programs.

Start smarter. Move faster.

PDXpress

PDXpress delivers pre-configured panels of CDX models, each grouped by key genetic alterations like KRAS or EGFR and paired with its matched PDX. This built-in continuity lets you launch studies in vitro knowing your in vivo transition is already secured. Ready-to-run curated panels shorten setup time, simplify model selection, and speed up actionable insights.

Explore PDXpress Panels

From CDX booking to parallel PDX — automatically.

PDXcelerate

PDXcelerate reserves parallel PDX capacity the moment you book CDX, ensuring in vivo continuity from day one. There’s no risk, no added cost, and no penalty should you choose not to move forward  - your PDX models are simply ready when you are. This seamless approach de-risks early decisions with clinically relevant CDX data, helping you prioritize compounds faster and move effortlessly from CDX screening to in vivo validation.

Reserve Your Parallel PDX Capacity Risk-Free

Flexible Study Formats

Champions’ CDX platform supports subcutaneous, orthotopic, and disseminated tumor models, allowing researchers to select the study format that best fits their program. For immune relevant applications, models can also be run in humanized systems to evaluate immune cell dynamics and immunotherapy strategies. This flexibility ensures that CDX studies are not one size fits all but instead tailored to the scientific question being asked.
flexible_stock_16x9
Platforms_05

Get started

Partnering with Champions

Working with Champions means more than accessing a list of models. Our scientific team collaborates with you to design studies that maximize translational impact, from proof of concept validation to ADC development. Every element of our CDX platform is built to connect with the broader Champions ecosystem, Ex Vivo, PDX, and multi omic platforms, ensuring continuity across your research program.

FAQ

Frequently Asked Questions

They are applied for early proof of concept studies, resistance modeling, target validation, and combination therapy testing, providing fast, reproducible data to guide program direction.

Each model is in vivo efficacy validated, with standardized growth curves starting at randomization and responses to standards of care documented for comparability.

Our portfolio includes solid tumors, hematologic malignancies, and rare cancers, with select models exhibiting high target expression ideal for ADC and radiopharmaceutical development.

We support subcutaneous, orthotopic, and disseminated models, as well as humanized formats for immune relevant studies.

It allows researchers to filter models by indication, mutation, and expression, simplifying and accelerating study planning.

By offering high expression models that allow early validation of target engagement and therapeutic payload effectiveness.

CDX models are the starting point, with seamless transition into Ex Vivo assays, PDX, and integration with Lumin Bioinformatics for translational continuity.

Yes, Champions is proactively expanding FFPE and TMA availability, providing clients with valuable tools for target validation and biomarker discovery.

With validated models and the Cell Line Select Tool, studies can be launched rapidly. Our team collaborates with you to align design and timelines.

Explore the Cell Line Select Tool to review available models or contact our scientific team for guidance on designing your CDX study.